Competition Commission launches probe into cancer drug prices in SA
'We think that the reason is excessive pricing by the participants in the market. We have to investigate and bring people to book'
14 June 2017 - 06:27
South Africa's competition watchdog has launched an investigation into three drug companies accused of over-charging for cancer medicines, the agency's chief said on Tuesday. Tembinkosi Bonakele, head of the Competition Commission, said the agency would investigate Aspen Pharmacare, Africa's biggest generic drug maker, U.S. company Pfizer and Swiss-based Roche Holding.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.